In GC, adjuvant chemotherapy regiments containing the ICD inducer oxaliplatin altered immune cell invasion and subtype by significantly reducing FOXP3+ Treg cells and increasing the diversity of CD8+ cytotoxic T cells and TCR in GC [22]. The gene discussed is FOXP3; the disease is gastric cancer.